Genocea Biosciences (Cambridge, MA) a preclinical-stage therapeutic vaccine developer focused on chlamydia trachomatis, streptococcus pneumonia and herpes simplex virus type 2 infections, closed a $35M Series B financing. Participants include Johnson & Johnson Dev Corp., Skyline Ventures, MP Healthcare Management, SR One, Auriga Partners, Cycad Group, Alexandria Real Estate Equities, Lux Capital Management, Polaris Venture Partners and Morningside Ventures.